口腔状細胞がんの分子メカニズムと遺伝的景観を解明する:疾患の複雑性,利用可能な治療法,および将来の検討
PubMedで要約を見る
まとめ
この要約は機械生成です。口腔状細胞癌 (OSCC) は複雑で,生存率は低い. このレビューでは,OSCCの治療と患者の治療結果を改善するための分子経路,遺伝学,および微生物群を調査しています.
科学分野
- 腫瘍学
- 分子生物学
- 遺伝学
背景
- 口腔状細胞癌 (OSCC) は,その異質性と複雑な分子基盤のために重要な課題を提示します.
- OSCCの5年生存率は最適以下であり,改善された治療戦略の緊急の必要性を強調しています.
- 現在の新興治療法では OSCC患者にとって 治療結果の改善には しばしば失敗します
研究 の 目的
- OSCCの発達に 関わる重要な分子経路を 検討する.
- OSCCの進行における遺伝的感受性と口腔微生物群の役割を調査する.
- OSCC管理のための免疫療法を含む現在のおよび将来の治療戦略を分析する.
主な方法
- OSCCにおける分子経路に関する包括的な文献レビュー.
- OSCCの感受性に寄与する遺伝的要因の分析
- OSCCの進歩に対する微生物群の影響の検討
- 現代的な治療方法と免疫療法の評価
主要な成果
- OSCCは複雑な分子経路と 多様な遺伝子環境で特徴付けられています
- 口腔の微生物群はOSCCの進行に重要な役割を果たします.
- 現在の治療法は 患者の生存と生活の質の改善に 限界があります
結論
- OSCCの分子複雑性を理解することは 効果的な治療法の開発に不可欠です
- 免疫療法と微生物群の影響への対処は,将来のOSCC治療に希望を示しています.
- 研究と臨床応用の間のギャップを埋めるのは,OSCCにおける患者の成果と生活の質を改善するために不可欠です.
関連する概念動画
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...

